Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M105,688Revenue $M40,159Net Margin (%)17.6Z-Score2.2
Enterprise Value $M130,924EPS $3.4Operating Margin %22.5F-Score6
P/E(ttm))17.1Cash Flow Per Share $0Pre-tax Margin (%)21.0Higher ROA y-yY
Price/Book14.010-y EBITDA Growth Rate %3.2Quick Ratio0.7Cash flow > EarningsY
Price/Sales3.05-y EBITDA Growth Rate %2.6Current Ratio1.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-22.6ROA % (ttm)10.4Higher Current Ratio y-yN
Dividend Yield %6.0Insider Buy (3m)0ROE % (ttm)68.0Less Shares Outstanding y-yY
Payout Ratio %93.0Shares Outstanding M2,402ROI % (ttm)14.0Gross Margin Increase y-yN

Gurus Latest Trades with GSK

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GSKHOTCHKIS & WILEY 2014-09-30 Add0.98%$46.29 - $54.52
($49.01)
$ 44-10%Add 118.31%10,804,564
GSKCharles Brandes 2014-09-30 Add0.56%$46.29 - $54.52
($49.01)
$ 44-10%Add 36.63%3,415,717
GSKIrving Kahn 2014-09-30 Buy 0.38%$46.29 - $54.52
($49.01)
$ 44-10%New holding, 51000 sh.51,000
GSKNWQ Managers 2014-09-30 Add0.03%$46.29 - $54.52
($49.01)
$ 44-10%Add 39.82%208,125
GSKDavid Dreman 2014-09-30 Buy 0.01%$46.29 - $54.52
($49.01)
$ 44-10%New holding, 1328 sh.1,328
GSKDodge & Cox 2014-09-30 Reduce-1.11%$46.29 - $54.52
($49.01)
$ 44-10%Reduce -35.93%38,589,161
GSKHOTCHKIS & WILEY 2014-06-30 Add0.93%$51.55 - $56.39
($54.16)
$ 44-19%Add 13358.6%4,949,118
GSKCharles Brandes 2014-06-30 Add0.21%$51.55 - $56.39
($54.16)
$ 44-19%Add 15.52%2,500,048
GSKJohn Rogers 2014-06-30 Add0.21%$51.55 - $56.39
($54.16)
$ 44-19%Add 49.33%988,772
GSKJames Barrow 2014-06-30 Buy 0.02%$51.55 - $56.39
($54.16)
$ 44-19%New holding, 270900 sh.270,900
GSKPRIMECAP Management 2014-06-30 Reduce-0.25%$51.55 - $56.39
($54.16)
$ 44-19%Reduce -43.82%5,156,449
GSKJohn Rogers 2014-03-31 Add0.16%$50.9 - $56.66
($54.07)
$ 44-19%Add 57.21%662,150
GSKHOTCHKIS & WILEY 2014-03-31 Buy 0.01%$50.9 - $56.66
($54.07)
$ 44-19%New holding, 36773 sh.36,773
GSKJohn Hussman 2014-03-31 Reduce-0.38%$50.9 - $56.66
($54)
$ 44-18%Reduce -23.61%323,500
GSKVanguard Health Care Fund 2014-03-31 Sold Out -0.11%$50.9 - $56.66
($54)
$ 44-18%Sold Out0
GSKNWQ Managers 2014-03-31 Reduce-0.03%$50.9 - $56.66
($54.07)
$ 44-19%Reduce -28.91%148,800
GSKJohn Hussman 2013-12-31 Add1.51%$49.31 - $53.68
($51.87)
$ 44-15%Add 1702.13%423,500
GSKJohn Rogers 2013-12-31 Add0.19%$49.31 - $53.68
($51.87)
$ 44-15%Add 208.93%421,201
GSKCharles Brandes 2013-12-31 Add0.16%$49.31 - $53.68
($51.87)
$ 44-15%Add 13.11%2,145,461
GSKJoel Greenblatt 2013-12-31 Buy 0.11%$49.31 - $53.68
($51.87)
$ 44-15%New holding, 83452 sh.83,452
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GSK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GSK Ken Fisher 2014-12-3110,765,0040.450.95-6.3%
GSK Irving Kahn 2014-09-3051,00000.38New Buy
GSK David Dreman 2014-09-301,32800.01New Buy
GSK HOTCHKIS & WILEY 2014-09-3010,804,5640.451.8+118.31%
GSK NWQ Managers 2014-09-30208,1250.010.11+39.82%
GSK Charles Brandes 2014-09-303,415,7170.142.1+36.63%
GSK John Rogers 2014-09-301,005,6340.040.6+1.71%
GSK Ken Fisher 2014-09-3011,488,5940.481.1+1.08%
GSK John Hussman 2014-09-30323,5000.011.3
GSK James Barrow 2014-09-30270,9000.010.02
GSK Jean-Marie Eveillard 2014-09-30100
GSK Joel Greenblatt 2014-09-3083,46200.04-0.08%
GSK Tweedy Browne 2014-09-30140,2780.010.15-1.29%
GSK PRIMECAP Management 2014-09-304,874,6350.20.24-5.47%
GSK Dodge & Cox 2014-09-3038,589,1611.611.7-35.93%
Premium Most recent portfolio changes are included for Premium Members only!


GSK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLCFormer 10% Owner (1) 2014-10-27Sell11,315,825$5.29753.69view
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$12276.33view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$14222.57view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$12276.33view

Press Releases about GSK :

    Quarterly/Annual Reports about GSK:

      News about GSK:

      Articles On GuruFocus.com
      Tumor Drug Takes The Focus At OncoMed Pharmaceuticals Jan 29 2015 
      Gilead Sciences Still has More Upside Jan 22 2015 
      Johnson & Johnson Riding High On Ebola Vaccines Jan 21 2015 
      set Jan 11 2015 
      tester Dec 18 2014 
      Weekly 3-Year Low Highlights: RDS.B, GSK, WPZ, CLR Dec 14 2014 
      Pfizer Spreading Its Wings Into A New Domain Of Life Sciences Dec 09 2014 
      The Top 5 European Stocks Held During Q3 Nov 25 2014 
      Jeff Auxier Buys Berkshire Hathaway in Third Quarter Nov 18 2014 
      Irving Kahn Starts New Position In GlaxoSmithKline Nov 13 2014 

      More From Our Partners
      Novartis (NVS) Up on Earnings and Revenue Beat in Q4 - Analyst Blog Jan 28 2015 - ZACKS

      More From Other Websites
      The $25B GSK-Novartis deal clears major hurdle Jan 28 2015
      12:19 pm GlaxoSmithKline confirms it has received clearance from the European Commission of its... Jan 28 2015
      Regulatory update on three-part transaction with Novartis Jan 28 2015
      Novartis (NVS) Up on Earnings and Revenue Beat in Q4 - Analyst Blog Jan 28 2015
      Why You Should — And Shouldn’t — Buy GlaxoSmithKline plc Jan 28 2015
      Pfizer's Prevenar 13 Wins CHMP Backing for Expanded Use - Analyst Blog Jan 26 2015
      GSK expands its portfolio of medicines in the US for patients with asthma and COPD Jan 26 2015
      Will Novartis' (NVS) Earnings Disappoint Expectations in Q4? - Analyst Blog Jan 23 2015
      GSK-Parexel partnership takes first steps following layoffs announcement Jan 23 2015
      Glaxo tackles fight against Ebola Jan 23 2015
      Is GlaxoSmithKline plc’s Dividend About To Be Cut? Jan 21 2015
      Africa's Consumer Economy Jan 21 2015
      Stocks: Why earnings matter? Jan 20 2015
      GlaxoSmithKline, plc (GSK): New Analyst Report from Zacks Equity Research - Zacks Equity Research... Jan 20 2015
      OncoMed Starts Expansion Stage Study for Solid Tumor Drug - Analyst Blog Jan 16 2015
      Why Now Is The Perfect Time To Buy GlaxoSmithKline plc Jan 16 2015
      Isis Pharmaceuticals Earns Milestone Payment from Biogen - Analyst Blog Jan 15 2015
      Vical Up on Deal with AnGes to Develop Ebola Treatment - Analyst Blog Jan 15 2015
      5 Stunning Pharma Stocks: GlaxoSmithKline plc, AstraZeneca plc, Shire PLC, BTG plc & Hikma... Jan 13 2015
      More Rotavirus Vaccination Means Less Rotavirus Jan 12 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK